236 related articles for article (PubMed ID: 18381107)
1. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.
Zhang MM; Gopal AK
Semin Hematol; 2008 Apr; 45(2):118-25. PubMed ID: 18381107
[TBL] [Abstract][Full Text] [Related]
2. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
3. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
Molina A; Krishnan A; Fung H; Flinn IW; Inwards D; Winter JN; Nademanee A
Curr Stem Cell Res Ther; 2007 Sep; 2(3):239-48. PubMed ID: 18220907
[TBL] [Abstract][Full Text] [Related]
4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
Shimoni A; Zwas ST
Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday RD; Storer BE; Sorror ML; Sandmaier BM; Guthrie KA; Maloney DG; Rajendran JG; Pagel JM; Flowers ME; Green DJ; Rezvani AR; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2015 Feb; 21(2):281-7. PubMed ID: 25445025
[TBL] [Abstract][Full Text] [Related]
9. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Gopal AK; Press OW; Wilbur SM; Maloney DG; Pagel JM
Blood; 2008 Aug; 112(3):830-5. PubMed ID: 18502830
[TBL] [Abstract][Full Text] [Related]
10. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
[TBL] [Abstract][Full Text] [Related]
11. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
Schaefer-Cutillo J; Friedberg JW
Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Philippe L; Helias P; Puyraveau M; Boulahdour H; Deconinck E; Daguindau E
Bone Marrow Transplant; 2016 Aug; 51(8):1140-2. PubMed ID: 27042844
[No Abstract] [Full Text] [Related]
14. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
[TBL] [Abstract][Full Text] [Related]
15. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma.
Krishnan A; Palmer JM; Tsai NC; Simpson JR; Nademanee A; Raubitschek A; Thomas SH; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):441-50. PubMed ID: 21801706
[TBL] [Abstract][Full Text] [Related]
16. Updated Results of Rituximab Pre- and Post-BEAM with or without
Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
[No Abstract] [Full Text] [Related]
17. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L; Guidetti A; Tarella C; Magni M; Matteucci P; Seregni E; Chiesa C; Bombardieri E; Di Nicola M; Carlo-Stella C; Gianni AM
J Clin Oncol; 2008 Nov; 26(32):5175-82. PubMed ID: 18854569
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.
Shimoni A; Nagler A
Leuk Lymphoma; 2007 Nov; 48(11):2110-20. PubMed ID: 17891639
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
20. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
Winter JN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]